Tango Therapeutics, Inc.
TNGX evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $3.83B
- Lead Asset:
- TNG260 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for TNGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TNGX
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company developing precision cancer medicines, primarily focused on PRMT5 inhibitors for MTAP-deleted cancers, with no approved products and no revenue from product sales.
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 8 clinical trials for Tango Therapeutics, Inc..
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company developing precision cancer medicines, primarily focused on PRMT5 inhibitors for MTAP-deleted cancers, with no approved products and no revenue from product sales.
- Cash & equivalents of $345.6M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$55.3M as of 2026-06-30 [sec].
- Lead PRMT5 inhibitor vopimetostat (TNG462) is in Phase 1/2 trials, with a pivotal study planned in second line pancreatic cancer in 2026 [sec · filed 2026-04-17].
- TNG456, a brain-penetrant PRMT5 inhibitor, began Phase 1/2 dosing in May 2025 for CNS cancers including glioblastoma [sec_mda · as of 2026-08-11].
- Cash runway extends into 2028, beyond anticipated key data inflection points [news · published 2026-05-13].
What works
- Strong cash position of $345.6M as of 2026-06-30 provides runway into 2028 [sec].
- Vopimetostat plus zoldonrasib combination showed a 52% ORR and 96% DCR in pancreatic cancer patients as of May 28, 2026 [sec_mda · as of 2026-08-11].
- Multiple clinical programs advancing, including a planned pivotal study for vopimetostat in second line pancreatic cancer in 2026 [sec · filed 2026-04-17].
What to weigh
- No approved products and no revenue from product sales; the company has never generated product revenue [sec_mda · as of 2026-03-05].
- Net loss of $55.3M for the quarter ended 2026-06-30, with expenses expected to increase substantially [sec] [sec_mda · as of 2026-08-11].
- Deprioritizing TNG260 program, indicating resource reallocation and potential pipeline narrowing [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Vopimetostat plus zoldonrasib combination efficacy
“We observed an ORR of 52%, a 16 74% six-month progression free survival rate, and 96% DCR in these patients.”
SEC MD&A · August 11, 2026
No approved products and no product revenue
“We have no products approved for commercial sale and therefore have never generated any revenue from product sales”
SEC MD&A · March 5, 2026
Cash runway into 2028
“Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points”
News · May 13, 2026
Catalyst timeline
- 2022-03-23 · Phase2_Start: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors — Initiation of Phase 1/2 trial for TNG908, an early PRMT5 inhibitor candidate.
- 2023-05-26 · Phase2_Start: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors — Start of Phase 1/2 trial for vopimetostat (TNG462), the lead PRMT5 inhibitor.
- 2023-06-12 · Phase2_Start: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as a Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors — Initiation of Phase 1/2 trial for TNG260, which is now being deprioritized.
Risks & what to watch (3)›
Key risks
- No product revenue — Company has never generated revenue from product sales and does not expect to in the foreseeable future [sec_mda · as of 2026-03-05].
- Increasing expenses — Clinical development costs are expected to increase substantially with ongoing and planned trials [sec_mda · as of 2026-08-11].
- Pipeline deprioritization — TNG260 program is being deprioritized and shut down, reducing pipeline diversity [sec_mda · as of 2026-08-11].
What to watch
- Safety and efficacy update for vopimetostat monotherapy in lung cancer cohort expected in 2026 [sec_mda · as of 2026-08-11].
- Initial clinical data from TNG456 Phase 1/2 trial anticipated in the second half of 2026 [sec_mda · as of 2026-08-11].
- Phase 1/2 data from vopimetostat + RAS(ON) combination study in pancreatic cancer to be presented at 2026 ESMO Congress [news · published 2026-08-11].
- Pivotal study initiation for vopimetostat in second line pancreatic cancer planned for 2026 [sec · filed 2026-04-17].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Tango Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tango Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
194
Total value held
$3.73B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 13,300,620 | $278.2M |
| adage capital partners gp, l.l.c. | 12,809,485 | $268.0M |
| boxer capital management, llc | 10,876,219 | $227.5M |
| tcg crossover management, llc | 10,531,071 | $220.3M |
| fmr llc | 9,905,919 | $207.2M |
| farallon capital management llc | 9,097,411 | $190.3M |
| blackrock, inc. | 8,748,045 | $183.0M |
| woodline partners lp | 8,000,013 | $167.4M |
| nextech invest, ltd. | 7,266,081 | $152.0M |
| trv gp iv, llc | 6,374,574 | $133.4M |
Showing top 10 of 194 institutional holders of Tango Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 26.9%
- Days to cover
- 12.9
- Shares short
- 38,250,843
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TNGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tango Therapeutics, Inc.?
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company developing precision cancer medicines, primarily focused on PRMT5 inhibitors for MTAP-deleted cancers, with no approved products and no revenue from product sales.
What is Tango Therapeutics, Inc.'s lead drug candidate?
Tango Therapeutics, Inc.'s most advanced tracked candidate is TNG260 (Phase 1/Phase 2) for Non Small Cell Lung Cancer.
Who is the CEO of Tango Therapeutics, Inc.?
Dr. Malte Peters M.D. is the chief executive officer of Tango Therapeutics, Inc. (TNGX).
Where is Tango Therapeutics, Inc. headquartered?
Tango Therapeutics, Inc. (TNGX) is headquartered in Boston, MA, United States.
What therapeutic areas does Tango Therapeutics, Inc. focus on?
Tango Therapeutics, Inc. develops therapies across Oncology, Immunology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.